Rxwire
In the news · 48h FDA 39 Eli Lilly 19 Roche 9 Merck & Co. (MSD) 8 Johnson & Johnson 4 AbbVie 3 AstraZeneca 3 Novo Nordisk 3
Manufacturing & supply · first seen yesterday, updated yesterday

Novo's new strategy hinges on something it can't manufacture: investor trust

1 outlet Novo Nordisk

Novo has now reached the point where it can broaden its ambitions again, CEO Mike Doustdar told CNBC, but investors remain unconvinced.

Summary from CNBC Health & Science.

Coverage 1 article · 1 outlet

  1. CNBC Health & Science
    Novo's new strategy hinges on something it can't manufacture: investor trust